Currently out of the existing stock ratings of Adam Walsh, 57 are a BUY (90.48%), 6 are a HOLD (9.52%).

Adam Walsh

Work Performance Price Targets & Ratings Chart

Analyst Adam Walsh, carries an average stock price target met ratio of 71.56% that have a potential upside of 43.12% achieved within 299 days. Previously, Adam Walsh worked at STIFEL.

Adam Walsh’s has documented 120 price targets and ratings displayed on 16 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PHAS, PhaseBio Pharmaceuticals at 28-May-2020.

Wall Street Analyst Adam Walsh

Analyst best performing recommendations are on VRTX (VERTEX PHARMACEUTICALS).
The best stock recommendation documented was for VRTX (VERTEX PHARMACEUTICALS) at 7/18/2017. The price target of $154 was fulfilled within 1 day with a profit of $21.84 (16.53%) receiving and performance score of 165.25.

Average potential price target upside

of $29.02 (44.83%) on RETA (REATA PHARMACEUTICALS).
of $25.02 (24.78%) on ASND (ASCENDIS PHARMA AS).
of $24.17 (23.39%) on VRTX (VERTEX PHARMACEUTICALS).

CNCE Concert Pharmaceuticals CORT Corcept Therapeutics INSM Insmed DRRX Durect RARE Ultragenyx ALDX Aldeyra The PHAS PhaseBio Pharmaceuticals VRTX Vertex Pharmaceuticals GLPG Galapagos NV ADR RETA Reata Pharmaceuticals ASND Ascendis Pharma AS FGEN FibroGen GLMD Galmed Pharmaceuticals Ltd PTGX Protagonist Therapeutics SAGE Sage Therapeutic VRNA Verona Pharma PLC ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Stephen Kim (EVERCORE)